ÐÂÎÅ×ÊѶ
°ÐµãɸѡÁªºÏµ¥Ï¸°û²âÐòÔÚÖÐÒ©»îÐԳɷֹ¦ÄÜÑо¿ÖеÄÓ¦ÓÃ
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷ÕߣºÐ¡¸ß
- À´Ô´£º´ï¼ªÌع«ÖÚºÅ
¡¾¸ÅÒªÃèÊö¡¿¡°Ò©Ð§ÆÀ¼Û-°Ðϸ°ûÈ·ÈÏ-°Ð±êʶ±ð-ÉúÎïѧ¹¦ÄÜÈ·Ö¤¡±µÄÑо¿Ä£Ê½£¬ÎªÌìÈ»²úÎPС·Ö×Ó»¯ºÏÎïµÄ°Ð±êÈ·Ö¤ÌṩÁËÒ»ÖֿɲÙ×÷µÄÑо¿·¶Ê½£¬ÖúÁ¦ÖÐÒ½Ò©µÄÏÖ´ú»¯Óë¹ú¼Ê»¯¡£
°ÐµãɸѡÁªºÏµ¥Ï¸°û²âÐòÔÚÖÐÒ©»îÐԳɷֹ¦ÄÜÑо¿ÖеÄÓ¦ÓÃ
¡¾¸ÅÒªÃèÊö¡¿¡°Ò©Ð§ÆÀ¼Û-°Ðϸ°ûÈ·ÈÏ-°Ð±êʶ±ð-ÉúÎïѧ¹¦ÄÜÈ·Ö¤¡±µÄÑо¿Ä£Ê½£¬ÎªÌìÈ»²úÎPС·Ö×Ó»¯ºÏÎïµÄ°Ð±êÈ·Ö¤ÌṩÁËÒ»ÖֿɲÙ×÷µÄÑо¿·¶Ê½£¬ÖúÁ¦ÖÐÒ½Ò©µÄÏÖ´ú»¯Óë¹ú¼Ê»¯¡£
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷ÕߣºÐ¡¸ß
- À´Ô´£º´ï¼ªÌع«ÖÚºÅ
- ·¢²¼Ê±¼ä£º2022-11-17 14:17
- ·ÃÎÊÁ¿£º
ÖÐÒ½ÖÎÁÆ°©Ö¢·ÖΪ“·öÕý”ºÍ“ìîа”Á½¸ö·½Ã棬·öÕý¼´Í¨¹ýµ÷½Ú×ÔÉíÃâÒß¹¦ÄÜÀ´´ïµ½¿¹°©Ä¿µÄ¡£ìîаÔòÖ±½Ó¶Ô¸¶²¡ÔÒÖÖÆÖ×ÁöÉú³¤¡£ÆäÖУ¬·öÕý¹Ì±¾·¨ÊÇ´«Í³ÖÐҽҩѧµÄ¾«»ª£¬ÊÇÖÐÒ½·ÀÖÎÖ×ÁöÖеÄÖ÷ÒªÌØÉ«¡£
ÌرðÊÇÖÐÒ½ÁÙ´²Öڶ࿹Ö×ÁöÑé·½Öж¼º¬ÓлÆÜγɷ֣¬Ö÷Òª·¢»ÓÆä“·öÕý¿¹°©”µÄ×÷Óᣵ«ÊÇ»ÆÜο¹Ö×Áö×÷ÓõĻúÖÆÉв»Çå³þ¡£
2022Äê10Ô£¬ÄϾ©ÖÐÒ½Ò©´óѧ³Ìº£²¨ÍŶÓÁªºÏÄϾ©´óѧËïÑóÍŶÓÔÚJ Immunother Cancer£¨IF=12.469£©·¢±íÁËÌâΪ“Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation”µÄÑо¿³É¹û£¬·¢ÏÖ»ÆÜλîÐԳɷֻ·»ÆÜδ¼£¨CAG£©¿É°ÐÏò×éÖ¯µ°°×øB¼õÉÙÖ×Áöϸ°ûÉÏMHC-IµÄ½µ½â£¬´Ó¶øÔöÇ¿CD8+Tϸ°û½éµ¼µÄ¿¹Ö×ÁöÃâÒß¡£
| 01¡¢»·»ÆÜδ¼£¨CAG£©ÒÖÖÆÖ×ÁöÉú³¤µÄ±íÐÍÈ·ÈÏ
Ñо¿Ê×ÏÈÀûÓÃMC38ºÍCT26СÊóÒÆÖ²ÁöÄ£ÐÍÀ´¼ì²âCAGµÄ¿¹Ö×Áö×÷Óã¬ÊµÑé½á¹û·¢ÏÖCAGÄܹ»ÏÔÖøÒÖÖÆÖ×ÁöµÄÉú³¤£¨Í¼1£©¡£
ͼ1 »·»ÆÜδ¼ÒÖÖÆÖ×ÁöÉú³¤
02¡¢µ¥Ï¸°û¼¼Êõ½Òʾ»·»ÆÜδ¼ÔöÇ¿Ö×Áöϸ°û¿¹ÔµÝ³Ê
ΪÁ˽ÒʾCAGÒÖÖÆÖ×ÁöÉú³¤µÄ¾ßÌå»úÖÆ£¬Ñо¿Ê¹ÓÃscRNA-seqºÍscATAC-seq¼¼Êõ¶ÔÖ×Áö×éÖ¯½øÐÐÁË·ÖÎö£¬½á¹û¿ÉÒÔ½«Ï¸°ûȺ·ÖΪËÄ×飺°©Ï¸°û¡¢³ÉÏËάϸ°û¡¢¹ÇËèϸ°ûºÍÁÜ°Íϸ°û£¬ÆäÖа©Ï¸°û·ÖΪ8¸öÑÇ×飨ͼ2A£©¡£¶ÔÖ×Áöϸ°ûȺµÄ·ÖÎö·¢ÏÖ£¬¿¹Ô³ÊµÝÏà¹Øͨ·ÔÚ¶à¸öϸ°ûȺÖÐÏÔÖø¸»¼¯£¨Í¼2B£©£¬²¢ÇÒ¿¹Ô³ÊµÝÏà¹Øͨ·Ïà¹Ø»ùÒòÔÚCAG×éµÄ±í´ïˮƽÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×飨ͼ2C£©¡£½øÒ»²½Ê¹ÓÃscATAC-seq·ÖÎöÁËCAG´Ù½øÖ×Áöϸ°û¿¹Ô³ÊµÝµÄ¾ßÌåÔÒò£¬·¢ÏÖCAG´¦Àí×éµÄÖ×Áöϸ°ûȺ¸ß¶È±í´ïת¼Òò×ÓFos¡¢Junb¡¢Jund¡¢Fosb ºÍFosl1£¨Í¼2D£©£¬Í¨¹ý¹¹½¨×ªÂ¼Òò×ÓÓëÏàÓ¦»ùÒòÏ໥×÷ÓõÄͼÆ×·¢ÏÖCAG´Ù½øÁËÖ×Áöϸ°û¿¹Ô³ÊµÝÏà¹Ø»ùÒòµÄ±í´ï£¨Í¼2E£©¡£½á¹û±íÃ÷£¬CAG¿ÉÒÔ´Ù½ø¿¹Ô³ÊµÝÏà¹Ø»ùÒòת¼Òò×ӵıí´ï£¬´Ó¶øÔöÇ¿Ö×Áöϸ°ûµÄ¿¹Ô³ÊµÝ¹¦ÄÜ¡£
ͼ2 »·»ÆÜδ¼ÔöÇ¿Ö×Áöϸ°û¿¹Ô³ÊµÝ
| 03¡¢»·»ÆÜδ¼·¢»Ó¿¹Ö×Áö×÷ÓõÄÌض¨°Ðµ°°×È·ÈÏ
ÔÚÈ·¶¨CAGµÄÖ÷Òª×÷ÓÃÓÚÖ×Áöϸ°ûÒÔºó£¬ÎªÁËÈ·¶¨CAG·¢»Ó¿¹Ö×Áö×÷ÓõÄÌض¨°Ðµ°°×£¬Ñо¿ÈËÔ±ºÏ³ÉÁË CAG µÄÉúÎïËØÑÜÉúÎֻÓÐ3-OH¿ÉÒÔ·´Ó¦£©£¬»îÐÔʵÑé·¢ÏÖÉúÎïËرê¼ÇµÄCAGͬÑù´Ù½øСÊóMC38Ö×Áöϸ°ûϵÖп¹Ô³ÊµÝÏà¹Ø»ùÒò£¨H2-K1¡¢Cd74ºÍAnxa£©µÄ±í´ï£¬¶Ô»îÐÔûÓÐÓ°Ïì¡£Ëæºó£¬Í¨¹ý°Ð±êÏìÓ¦¿É¼°ÐÔ·ÖÎö¼¼Êõ£¨Target-Responsive Accessibility Profiling, TRAP£©Ñ°ÕÒCAGµÄ°Ð±êµ°°×£¨Í¼3A£©£¬Ñ¡ÔñFC≥2 ÇÒp≤0.05µÄµ°°××÷ΪCAGµÄºòÑ¡°Ðµ°°×£¬·¢ÏÖ×éÖ¯µ°°×øB£¨CTSB£©ÎªCAGÖ±½Ó°Ðµã£¨Í¼3B£©£¬½øÒ»²½Í¨¹ýϸ°ûÈÈǨÒÆ£¨Í¼3C£©¡¢Î¢Á¿ÈÈÓ¾£¨MST£©£¨Í¼3D£©¡¢·Ö×ӶԽӺ͵ãÍ»±äµÈ¼¼ÊõÑéÖ¤ÁËCAGºÍ°Ð±êµ°°××éÖ¯µ°°×øBÖ±½Ó½áºÏ¡£
ͼ3»·»ÆÜδ¼·¢»Ó¿¹Ö×Áö×÷Óõİе°°×È·ÈÏ
| 04¡¢»·»ÆÜδ¼Í¨¹ý°Ðµ°°×CTSBµ÷¿ØÖ×Áöϸ°û¿¹Ô³ÊµÝ¹¦ÄÜ
Ö×Áö¿¹Ô³ÊµÝÊÇÓÉMHC-I½éµ¼µÄ£¬ÇÒÓÐÑо¿±íÃ÷MHC-IÔÚÈÜøÌåÖнµ½âµ¼ÖÂÖ×ÁöÃâÒßÌÓÒݵķ¢Éú£¬Ñо¿ÈËÔ±ÍƲâCAG ÊÇ·ñÒ²¿ÉÒÔͨ¹ýÆä°Ðµ°°×CTSBµ÷½Úϸ°ûĤÉÏMHC-IµÄ±í´ï¡£Í¨¹ý½«CTSBÍ»±äÖÊÁ£×ªÈ¾µ½ÈËHCT-116ϸ°ûÖз¢ÏÖתȾY75A¡¢A77VºÍG198VÍ»±äÖÊÁ£ºó£¬CAGÔöÇ¿CD74ºÍHLA-A»ùÒò±í´ïµÄ¹¦Äܱ»ÆÆ»µ£¨Í¼4A£©£¬±íÃ÷CAGÒÖÖÆCTSB½éµ¼µÄÈÜøÌåÖÐMHC-IµÄ½µ½â£¬²¢´Ù½øÁËMHC-IÏòϸ°ûĤµÄÔÙ¾Û¼¯¡£Ö×ÁöÃâÒßÌÓÒÝÖ÷ÒªÊÇÓÉÓÚÖ×Áöϸ°û¿¹Ô³ÊµÝ¹¦ÄÜɥʧºÍÃâÒß¼ì²éµãÊܵ½ÒÖÖÆËùÖ£¬ÓÚÊÇÑо¿ÈËÔ±ÍƲâCAGÊÇ·ñ¿ÉÒÔÓëPD-1¿¹ÌåÁªºÏʹÓÃÀ´É±ËÀÖ×Áö£¬·¢ÏÖCAGºÍPD-1¿¹ÌåÁªºÏ×éµÄ¿¹Ö×ÁöЧ¹ûÓÅÓÚCAGºÍPD-1×飬¿¹Ô³ÊµÝÏà¹Ø»ùÒò H2-K1¡¢Psmb8 ºÍB2m Ò²µÃµ½ÁËÔöÇ¿£¨Í¼4B£©¡£
ͼ4 »·»ÆÜδ¼Í¨¹ýCTSBµ÷¿ØÖ×Áöϸ°û¿¹Ô³ÊµÝ¹¦ÄÜ
| ×ܽáÓëÌÖÂÛ
Ä¿Ç°ÎÒ¹úÖÐÒ©¿¹Ö×ÁöÑо¿´ó¶à¾Û½¹ÓÚҩЧÑо¿£¬µ«Æä¾ßÌåµÄ×÷Óðе㼰Ïà¹Ø»úÖÆÑо¿ÈÔ²»ÊǺÜÇå³þ£¬ÇÒ×÷ÓûúÖÆÓëÁÙ´²ÖÐÒ½ÀíÂÛµÄÈÚºÏÉÐÓÐǷȱ£¬Ó°ÏìÖÐÒ©µÄÏÖ´ú»¯¡£¸ÃÑо¿Í¨¹ýµ¥Ï¸°û¶à×éѧ²âÐò¡¢°ÐÏìÓ¦¿É¼°ÐÔ·ÖÎöµÈ¼¼Êõ£¬·¢ÏÖ·öÕýÀàÖÐÒ©»ÆÜλîÐԳɷÖCAG¿ÉÒÔͨ¹ý×éÖ¯µ°°×øB£¨CTSB£©ÒÖÖÆÖ÷Òª×éÖ¯ÏàÈÝÐÔ¸´ºÏÎï I£¨MHC-I£©½éµ¼µÄ½µ½âÀ´´Ù½øÖ×Áö¿¹Ô³ÊµÝ²¢ÔöÇ¿ CD8 T ϸ°ûµÄ¿¹Ö×ÁöÄÜÁ¦£¬Ñо¿³É¹û·á¸»ÁËÖÐÒ½“·öÕýÖΰ©”ÀíÂ۵ĿÆѧÄÚº¡£
ÖµµÃ×¢ÒâµÄÊÇ£º
¸Ã¿ÎÌâ½üÈÕÔÚActa Pharmaceutica Sinica B£¨IF=14.903£©ÉÏ·¢±íÁË“New opportunities and challenges of natural products research: When target identification meets single-cell multiomics”ΪÌâµÄ×ÛÊöÎÄÕ£¬Ìá³öÁË»ùÓڰбêÈ·Ö¤Ó뵥ϸ°û¶à×éѧÓлú½áºÏµÄÌìÈ»²úÎï»úÖÆÑо¿Ð²ßÂÔ¡£¶øÉÏÊö°¸Àý¾ÍÊǸòßÂÔµÄÒ»¸ö·Ç³£ºÃµÄ²ûÊÍ¡£
1£© ͨ¹ý¹¹½¨ºÏÊʵļ²²¡¶¯ÎïÄ£ÐÍ£¬ÑéÖ¤ÌìÈ»²úÎï¶Ô¸ÃÄ£Ð͵ÄÖÎÁÆЧ¹û£»
2£© È¡¼²²¡Ä£ÐÍ·¢²¡²¿Î»µÄ×éÖ¯£¬½øÐе¥Ï¸°û¶à×éѧ²âÐò£¨°üÀ¨scRNA-seqºÍscATAC-seq·ÖÎöµÈ£©£¬¼ø¶¨¸øÒ©Ç°ºóÏÔÖø±ä»¯µÄ²îÒìϸ°ûÑÇȺ£»½øÒ»²½Ñ¡È¡²îÒìϸ°ûÑÇȺ×÷Ϊ°Ðϸ°û£»
3£© ÀûÓÃTRAP¡¢DARTS¡¢20KоƬµÈ²ßÂÔÑ°ÕÒÌìÈ»²úÎïÔÚ°Ðϸ°ûÄڵĽáºÏµ°°×£¬²¢Ê¹ÓÃITC¡¢SPR¡¢MSTµÈ¼¼Êõ½øÐаб군°×µÄ½áºÏÈ·Ö¤£»
4£© ½áºÏ¶¯ÎïˮƽµÄ»ùÒòÇóý/ÇÃÈëºÍϸ°ûˮƽµÄÇõÍ/¹ý±í´ïÒÔ¼°ÀàÆ÷¹ÙˮƽÑéÖ¤¸Ã°Ð±êµ°°×µÄÉúÎïѧ¹¦ÄÜ£¬²¢¶ÔÏÂÓÎͨ·½øÐзÖÎöÒÔÃ÷È·ÌìÈ»²úÎïÓë¸Ã°Ð±êµ°°×½áºÏÓ°Ïì¼²²¡½øÕ¹µÄ»úÖÆ¡£
×ÜÖ®£¬µ¥Ï¸°û×éѧ¼¼ÊõÔÚ·¢ÏÖҩЧÎïÖÊ¡¢¹¹½¨×÷ÓÃÍøÂçºÍ²ûÃ÷ÕûºÏµ÷½Ú»úÖƵȷ½ÃæÓÐמ޴óµÄÓ¦ÓÃDZÁ¦£¬ÎªÖÐÒ½Ò©ÏÖ´úÑо¿´øÀ´ÁËлúÓö¡£
´ï¼ªÌØרעÓÚÒ©°ÐÑо¿£¬¿ÉΪÄúÑ°ÕÒÒ©Îï°ÐµãÌṩ¶àÖÖ¶àÑùµÄרҵµÄ¼¼Êõ·þÎñºÍ½â¾ö·½°¸£¬ÖúÄú½â¾öÒ©Îï°Ðµã-»úÀíÑо¿Öеĸ÷ÖÖÄÑÌâ¡£
´ï¼ªÌØÕë¶ÔÓÚÖÐÒ©¼°Ð¡·Ö×ÓÒ©ÎïÑо¿£¬½¨Á¢ÁËÒ»Ì×ÍêÕûµÄ¼¼Êõ·þÎñÌåϵ£º
1£©ÖÐÒ©/¸´·½µÄÓÐЧ³É·Ö¼°´úл²úÎï·ÖÀëÓë¼ø¶¨£»
2£©ÑªÇå/×éÖ¯Ò©´ú¶¯Á¦Ñ§·ÖÎö
3£©Ð¡·Ö×Ó»¯ºÏÎïÉúÎïËØÅúÁ¿±ê¼Ç
4) С·Ö×Ӱеãɸѡ£º20KоƬ£¬IP/Pull down+ÖÊÆ×
5£©Ò©Îïµ÷¿ØÐźÅͨ·ɸѡ£ºÁ×Ëữ¿¹ÌåоƬ£¬µ°°×ÖÊ×éѧ
6£©ÍøÂçÒ©ÀíѧÓë¼ÆËã»ú·Ö×Ó¶Ô½Ó
7£©SPR±íÃæµÈÀë×Ó¹²Õñ£¨·Ö×Ó¶¯Á¦Ñ§£©
8£©ÌìÈ»²úÎﻯºÏÎï¿âÓ빦ÄÜ»¯ºÏÎïɸѡ·þÎñ
| Ïà¹ØÎÄÏ×
[1] Deng G, Zhou L, Wang B, et al. Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation. J Immunother Cancer, 2022 Oct;10(10):e004874.
[2] Yuyu Zhu, Zijun Ouyang, Haojie Du, et al. New opportunities and challenges of natural products research: When target identification meets single-cell multiomics. Acta Pharmaceutica Sinica B, 2022, 12(11) 4011-4039.
µØÖ·£ºÉϺ£ÊÐãÉÐÐÇøÂÌÖÞ»·Â·396Ū5´±4²ã
µç»°£º400-869-2936£¬021-33968791
ÓÊÏ䣺support@wayenbiotech.com
´«Õ棺021-33938792
QQ£º2120485725
Õ½ÂÔºÏ×÷
Õ½ÂÔºÏ×÷
| Full Moon | RayBiotech | CDI | IZON | Bio-Rad | R&D Systems | IsoPlexis | ÄÏÄ£ÉúÎï | Å·Ò×ÉúÎï | ÆäÃ÷ÐÅÏ¢ | ÃÀ¼ªÉúÎï | ÂóÌØ»æÆ× |
Ìرð˵Ã÷£º±¾ÍøËùÓÐÍøÒ³¾ùΪk8¿·¢(Öйú)Ô´´ÐÅÏ¢£¬×ªÔرØÐëÕ÷Çók8¿·¢(Öйú)ͬÒ⣬²¢Í¬Ê±×¢Ã÷±¾ÍøÃû³Æ¼°ÍøÖ·¡£